US Benchmarking Clinical Study

Recruiting now

Conditions studied: HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy, Cardiac Amyloidosis

In brief

The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failure and left ventricular hypertrophy, with or without transthyretin amyloidosis with cardiomyopathy (ATTR-CM), and in control subjects without heart failure or cardiomyopathy. The main question it aims to answer is: • Can SWV be used to measure myocardial and liver stiffness in the study's target populations? Researchers will compare patients with ATTR-CM, patients without ATTR-CM, and a control group to determine the distributions of SWV in each population. Participants will: * Have a standard cardiology assessment, including a physical exam, blood work, and an echocardiogram. * Undergo an investigational assessment with the eMyosound LYRA device to measure SWV in their myocardium and liver. * Have the investigational assessment repeated by a second observer to assess measurement reliability.

Key facts

Study ID

NCT07215715

Run by

eMyosound SAS

People needed

150

Starts

2025-09-16

Expected to finish

2026-07-01

Last updated by the study team

2025-10-20

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Inclusion Criteria Common to all three Study Arms:
• Male or female age ≥ 60 years
• Signed informed consent and able to comply with protocol
• Inclusion Criteria Common to the Heart Failure with non-reduced left ventricular ejection fraction (LVEF) with or without transthyretin amyloid cardiomyopathy (ATTR-CM) Arms:
• Patients meeting the Universal Definition of Heart Failure \& HeartShare study criteria.
• LVEF >40% on the last available imaging study
• Left ventricular hypertrophy (LVH) defined as left ventricular mass index (mass/BSA) in female > 95 g/m², in male > 115 g/m² according to American Society of Echocardiography/European Association of Cariology (ASE/EAC) guidelines42 OR as interventricular septum (IVS) thickness ≥12 mm
• Inclusion criterion specific to HF with non-reduced LVEF without ATTR-CM Arm:
• Negative (grade 0) Pyrophosphate (PYP) scintigraphy within 24 months prior to the enrolment in the study OR Simple Score <643 OR negative endomyocardial biopsy
• Inclusion criterion specific to HF with non-reduced LVEF with ATTR-CM Arm:
• ATTR-CM objectively confirmed and classified at any time prior to the enrollment in the study, with monoclonal protein AL amyloidosis ruled out, according to American Heart Association (AHA) 2020 criteria
• Inclusion criteria in Control Subjects:
• No diagnosis of HF or cardiomyopathy according to the universal definition of Heart Failure
• No diagnosis of Transthyretin amyloid cardiomyopathy (ATTR-CM) or Amyloid light-chain (AL) amyloidosis

You may not qualify if…

• Exclusion criteria common to the three arms:
• Pregnant OR pre-menopausal woman
• Vulnerable patients
• Acute Coronary Syndrome within 30 days
• Heart rate greater than 130 beats/minute at the time of the measurements
• Atrial fibrillation or flutter at the time of SWV measurement (history of AF is authorized provided they patient is in sinus rhythm at the time of the measurements)
• Any clinically significant cardiac arrhythmia at the time of SWV measurement
• Poor echogenicity preventing accurate ultrasound measurements
• Patients with segmental wall motion abnormalities thought to be due to myocardial infarction.
• Severe mitral or aortic valve disease (regurgitation or stenosis) excluded if the cause is other than ATTR (e.g., prolapse, endocarditis, prosthetic valve.)
• Severe tricuspid valve disease (regurgitation or stenosis) excluded if the causes are other than ATTR.
• Distance from skin to IVS ≥ 8 cm
• Any prosthetic mechanical valve
• Patients with mechanical cardiac assist devices other than pacemakers or defibrillators
• Heart, lung, liver or kidney transplant history or expected in the next year
• Severe renal impairment with eGFR < 15 mL/min/1.73m² or end-stage renal disease or patient on dialysis.
• Presence of any competing life-threatening risk over the next 12 months
• Complicated uncontrolled diabetes mellitus HbA1c ≥9% with target organ damage.
• Uncontrolled and persistent high-blood pressure with diastolic pressure > 100 mmHg or systolic pressure > 160 mmHg at the time of the measurement.
• Acute decompensated state such as volume overload, etc. in the opinion of the study investigator
• Skin abnormalities, infections, or open wounds at the site of the SVW measurement
• Liver disease, at least moderate
• Exclusion criteria in both the HF with non-reduced LVEF with or without ATTR-CM Arms:
• Known inherited cardiomyopathy, infiltrative cardiomyopathy (other than ATTR-CM for the study arm for ATTR-CM), cardiomyopathy from muscular dystrophies, cardiomyopathy with reversible causes (e.g., stress cardiomyopathy), hypertrophic cardiomyopathy or known pericardial constriction
• History of treatment for ATTR-CM with Transthyretin (TTR) depleters

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• Brigham and Women's Hospital — Boston, Massachusetts, United States (enrolling)
• Boston Medical Center — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.